Jeffrey W Meeusen
Overview
Explore the profile of Jeffrey W Meeusen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
513
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Narasimhan M, Cao J, Meeusen J, Remaley A, Martin S, Muthukumar A
Front Cardiovasc Med
. 2025 Mar;
12:1534460.
PMID: 40083824
No abstract available.
2.
Titan S, Lieske J, Meeusen J, Thorson S, Lin Y, Nowakowski G, et al.
Clin J Am Soc Nephrol
. 2025 Jan;
20(3):358-366.
PMID: 39874103
No abstract available.
3.
Stammler F, Grassi M, Meeusen J, Lieske J, Dasari S, Dubourg L, et al.
Diagnostics (Basel)
. 2024 Sep;
14(17).
PMID: 39272782
In the original publication [...].
4.
Cao J, Donato L, El-Khoury J, Goldberg A, Meeusen J, Remaley A
J Appl Lab Med
. 2024 Sep;
9(5):1040-1056.
PMID: 39225455
Background: The accurate measurement of blood lipids and lipoproteins is crucial for the clinical management of atherosclerotic disease risk. Despite progress in standardization, there are still significant variations in pre-analytical...
5.
Lam R, Manemann S, Seehusen K, Remaley A, St Sauver J, Jiang R, et al.
Lipids Health Dis
. 2024 Jul;
23(1):210.
PMID: 38965543
Background: Low-density lipoprotein cholesterol (LDL-C) is associated with atherosclerotic cardiovascular disease (ASCVD). Friedewald, Sampson, and Martin-Hopkins equations are used to calculate LDL-C. This study compares the impact of switching between...
6.
Block D, Lasho M, Donato L, Meeusen J
Am J Clin Pathol
. 2024 May;
162(4):356-368.
PMID: 38709595
Objectives: The aims of this study were to (1) establish the maximum allowable interference limits for hemolysis, lipemia, and icterus for chemistry analytes tested in body fluid samples and (2)...
7.
Churchill R, Gochanour B, Scott C, Vasile V, Rodeheffer R, Meeusen J, et al.
Biomarkers
. 2024 Apr;
29(4):161-170.
PMID: 38666319
Materials And Methods: The study assessed major adverse cardiac events (MACE) (myocardial infarction, coronary artery bypass graft, percutaneous intervention, stroke, and death. Cox proportional hazards models assessed apolipoprotein AI (ApoA1),...
8.
Seehusen K, Remaley A, Sampson M, Meeusen J, Larson N, Decker P, et al.
J Am Heart Assoc
. 2024 Apr;
13(8):e031878.
PMID: 38591325
Background: Clinical risk scores are used to identify those at high risk of atherosclerotic cardiovascular disease (ASCVD). Despite preventative efforts, residual risk remains for many individuals. Very low-density lipoprotein cholesterol...
9.
Wang Q, Meeusen J
J Appl Lab Med
. 2024 Feb;
9(3):586-598.
PMID: 38366867
Background: Estimated glomerular filtration rate (eGFR) has become incorporated into multiple clinical management situations. Historically, equations included a Black race coefficient, which lacked biological plausibility and created potential to exacerbate...
10.
Beunders R, Donato L, van Groenendael R, Arlt B, Carvalho-Wodarz C, Schulte J, et al.
Kidney Int Rep
. 2023 Nov;
8(11):2345-2355.
PMID: 38025210
Introduction: In clinical practice, kidney (dys)function is monitored through creatinine-based estimations of glomerular filtration rate (eGFR: Modification of Diet in Renal Disease [MDRD], Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]). Creatinine...